Abstract: Metastatic castration-resistant prostate cancer (mCRPC) is an incurable malignancy characterized by a poor prognosis. Approximately 15% to 30% of patients with mCRPC harbor alterations in homologous recombination repair (HRR) genes, such as BRCA1 and BRCA2, which render these tumors highly susceptible to poly(ADP-ribose) polymerase (PARP) inhibitors through the mechanism of synthetic lethality. BMN-673, also known as talazoparib, is a highly potent, relatively new PARP1/2 inhibitor that has demonstrated superior efficacy in vitro and in vivo compared to earlier generation PARP inhibitors like olaparib and rucaparib. Talazoparib is distinguished by its exceptional ability to trap PARP-DNA complexes and its unique radiosensitizing properties. Clinical trials, including the TALAPRO series, have highlighted its significant pharmacological activity and survival benefits in mCRPC patients, particularly when used as a monotherapy in HRR-deficient populations or in combination with androgen receptor pathway inhibitors (ARPIs) like enzalutamide. This review comprehensively examines the pharmacological activity, molecular mechanisms, structure-activity relationships, current limitations, and future therapeutic perspectives of talazoparib in the management of mCRPC.
1. Introduction
Prostate cancer remains a leading cause of cancer-related mortality worldwide. Despite the initial success of androgen deprivation therapy (ADT), most patients eventually progress to metastatic castration-resistant prostate cancer (mCRPC), an advanced and incurable stage of the disease with a median survival of approximately two to three years [3]. Genomic profiling of mCRPC has revealed that up to 30% of patients possess germline or somatic mutations in homologous recombination repair (HRR) genes, most notably BRCA1, BRCA2, and ATM [2][3]. These DNA repair defects create a therapeutic vulnerability that can be exploited by poly(ADP-ribose) polymerase (PARP) inhibitors via the concept of synthetic lethality [2].
BMN-673 (talazoparib) is a novel, orally efficacious PARP inhibitor that targets PARP-1 and PARP-2. It has emerged as a highly potent therapeutic agent, demonstrating impressive anticancer potential as a monotherapy in several pre-clinical and clinical studies [1]. Beyond its role as a single agent, talazoparib is being actively investigated in combination regimens to overcome resistance mechanisms and improve clinical outcomes in patients with advanced prostate cancer [2].
2. Pharmacological Activity
Talazoparib exhibits superior pharmacological efficacy at low nanomolar concentrations compared to other clinically relevant PARP inhibitors such as olaparib, rucaparib, and veliparib [1]. Its clinical activity in mCRPC has been robustly demonstrated across several key trials.
In the Phase II TALAPRO-1 study, talazoparib monotherapy (1 mg daily) was evaluated in mCRPC patients with HRR gene alterations who had previously progressed on taxane-based chemotherapy and androgen receptor-targeted therapy. The study reported an overall objective response rate (ORR) of 29.8%. The efficacy was most pronounced in patients with BRCA1/2 alterations, who achieved an ORR of 46%, whereas patients with PALB2 and ATM mutations showed ORRs of 25% and 12%, respectively [2][5].
The Phase III TALAPRO-2 trial investigated the combination of talazoparib and enzalutamide versus enzalutamide alone as a first-line therapy for mCRPC. The combination therapy successfully met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) compared to the control arm [2]. Furthermore, the ongoing Phase III TALAPRO-3 trial is evaluating this same combination in patients with metastatic hormone-sensitive prostate cancer (mHSPC) harboring HRR alterations [2].
Additionally, talazoparib possesses unique and potent radiosensitizing properties. It achieves strong radiosensitization at low nanomolar concentrations (e.g., 2 to 50 nM) across various cancer cell lines, a feature not observed to the same extent with other clinical PARP inhibitors [1].
3. Molecular Mechanism of Action
Talazoparib functions primarily by inhibiting the catalytic activities of the DNA repair enzymes PARP-1 and PARP-2. When DNA is damaged, PARP-1 is recruited to single-strand breaks to catalyze the formation of ADP-ribose polymers (PARylation), which recruits other repair proteins. By inhibiting this process, talazoparib prevents the repair of single-strand breaks, which subsequently degenerate into highly toxic double-strand breaks (DSBs) during DNA replication. In tumor cells lacking functional HRR pathways (e.g., BRCA1/2 mutations), these DSBs cannot be accurately repaired, leading to cell death through synthetic lethality [2][3].
A defining mechanistic feature of talazoparib is its exceptional ability to trap PARP-DNA complexes. Talazoparib is approximately 100-fold more potent at stereospecific PARP trapping than both olaparib and rucaparib. This trapped PARP-DNA complex is highly cytotoxic, as it physically blocks DNA replication forks [3][4][9].
Furthermore, talazoparib exerts its radiosensitizing effects by causing profound shifts in the balance of DSB repair pathways. It strongly inhibits classical non-homologous end-joining (c-NHEJ) and reciprocally increases DSB end-resection. This shift enhances error-prone DSB processing (such as alternative end-joining, alt-EJ), which robustly potentiates cell killing following ionizing radiation [1].
There is also a critical mechanistic interplay between PARP and the androgen receptor (AR). PARP1 is implicated in transcriptional regulatory functions that modulate AR activity, which is essential for prostate tumor growth. Conversely, AR blockade downregulates genes involved in DNA repair, inducing an "HRR-deficient" phenotype. This bidirectional relationship provides a strong molecular rationale for co-targeting AR and PARP concurrently [2].
4. Structure-Activity Relationship (SAR)
The chemical identity of talazoparib is (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one [4][10]. The specific stereochemistry of the molecule is crucial for its biological activity, enabling stereospecific PARP trapping [4][7]. This unique structural conformation allows talazoparib to bind to the NAD+ pocket of the PARP enzyme with exceptionally high affinity, locking the enzyme onto the DNA strand. This structural optimization is responsible for making talazoparib highly potent and orally efficacious, distinguishing its trapping efficiency and cytotoxicity profile from earlier PARP inhibitors [9][10].
5. Current Limitations
Despite its high potency, the clinical application of talazoparib faces several limitations:
Drug Resistance: Tumor resistance to PARP inhibitors is a significant clinical bottleneck. Mechanisms of acquired resistance include the development of BRCA2 reversion mutations, which restore HRR function and have been detected in the circulating cell-free DNA of mCRPC patients progressing on talazoparib [1][3].
Toxicity and Adverse Events: Talazoparib treatment is associated with hematologic toxicities, most notably anemia and neutropenia, as well as fatigue and nausea [7]. Furthermore, emerging reports indicate that long-term treatment with PARP inhibitors carries a risk of severe secondary malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), necessitating regular hematological monitoring [3][4].
Biomarker Dependence: The efficacy of talazoparib is highly dependent on the specific molecular subtype of the tumor. While patients with BRCA1/2 mutations show strong responses, those with alterations in other DNA repair genes, such as ATM or CDK12, exhibit minimal to dismal response rates, limiting the broader applicability of the drug as a monotherapy [2][3].
6. Future Perspectives
To overcome current limitations, future research is heavily focused on combination strategies and improved biomarker selection. Given talazoparib's unique radiosensitizing properties, combining it with radiotherapy (RT) is being actively pursued to overcome tumor resistance and enhance local control [1].
The synergistic effect of combining talazoparib with ARPIs (e.g., enzalutamide) is already showing promise in Phase III trials (TALAPRO-2 and TALAPRO-3) and is likely to move PARP inhibition into earlier stages of prostate cancer treatment, such as the metastatic hormone-sensitive setting [2]. Other promising combinations include pairing talazoparib with inhibitors of the DNA damage response, such as ATR inhibitors (e.g., ceralasertib), which induce replication stress and may overcome PARP inhibitor resistance regardless of baseline HRR status [2]. Combinations with immunotherapies, such as avelumab, are also under investigation in early-phase trials [3].
Finally, the refinement of predictive biomarkers is critical. The use of circulating tumor DNA (ctDNA) for non-invasive genomic profiling and the development of functional assays, such as RAD51 foci analysis, will help clinicians better identify which patients possess the "HRR-deficient" phenotype and are most likely to benefit from talazoparib therapy [2][5].
